logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
AZN
AstraZeneca PLC
183.86
300 x undefined
100 x undefined
bid
ask
-
5.76
3.04%
200 @ 06:31 AM
187.61 +3.75 (2.04%)
Ytd0.00%
1y28.65%
183.49
day range
187.56
137.22
52 week range
212.71
Open187.07Prev Close189.62Low183.49High187.56Mkt Cap285.14B
Vol2.11MAvg Vol1.98MEPS6.64P/E27.69Forward P/E23.34
Beta0.21Short Ratio0.68Inst. Own68.24%Dividend3.16Div Yield1.67
Ex Div Date02-20Earning07-2750-d Avg184.21200-d Avg183.291yr Est224.49

AZN News

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
prnewswire.com
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial o

SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereaf

Why Astrazeneca (AZN) Dipped More Than Broader Market Today
zacks.com
Why Astrazeneca (AZN) Dipped More Than Broader Market Today

Astrazeneca (AZN) closed at $183.86 in the latest trading session, marking a -3.04% move from the pr

AZN vs. ILMN: Which Stock Should Value Investors Buy Now?
zacks.com
AZN vs. ILMN: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably alrea

Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
zacks.com
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
zacks.com
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)

AZN's Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to

AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe
benzinga.com
AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe

AstraZeneca reported positive HPP trial data while Enhertu gained EU approval for HER2-positive soli

AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors
zacks.com
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors

AZN's Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to

FTSE 100 Live: London stocks fall over 100 points in broad sell-off
proactiveinvestors.com
FTSE 100 Live: London stocks fall over 100 points in broad sell-off

FTSE 100 falls 104 points to 10,426 Apple price hike weighs on tech stocks  Softbank sinks 14% in To

Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout
proactiveinvestors.com
Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout

Jefferies has reiterated its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) and named the dru

Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout
proactiveinvestors.co.uk
Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout

Jefferies has reiterated its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) and named the dru
benzinga.com
EU CHMP Recommends Approval Of Daiichi Sankyo and AstraZeneca's Datroway For First-Line Treatment Of

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datrow

HIVE Digital Technologies upsizes convertible note offering to support GPU purchases, data center expansion
proactiveinvestors.com
HIVE Digital Technologies upsizes convertible note offering to support GPU purchases, data center ex

HIVE Digital Technologies Ltd (TSX:HIVE, NASDAQ:HIVE, FRA:YO0, BVC:HIVECO) has announced the pricing

Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
zacks.com
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note

In the most recent trading session, Astrazeneca (AZN) closed at $185.68, indicating a +1.45% shift f

Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
benzinga.com
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model

As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod
benzinga.com
This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod

Major FDA wins for AstraZeneca: Truqap combination approved for advanced prostate cancer; Ultomiris

benzinga.com
AstraZeneca Announces Truqap Combination Approved In The U.S. As First And Only Targeted Treatment F

https://www.astrazeneca.com/media-centre/press-releases/2026/truqap-approved-in-us-for-prostate-canc

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
benzinga.com
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials

AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes

benzinga.com
'AstraZeneca's Obesity Pill Matches Rivals In Phase 2, Anchoring $5B Franchise Push; AstraZeneca Obe

https://endpoints.news/ada26-astrazeneca-glp-1-pill-cuts-weight-10-5-after-six-months/

AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease
benzinga.com
AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease

AstraZeneca's Ultomiris cut proteinuria by 46.6% in Phase 3 IgAN trial interim analysis, support

AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study
benzinga.com
AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study

AstraZeneca reports updated SERENA-6 data showing camizestrant improved PFS, PFS2 and ctDNA clearanc
benzinga.com
AstraZenica To Present Updated Phase III SERENA-6 Trial Results At ASCO Annual Meeting June 2

The updated results showed the camizestrant combination reduced the risk of disease progression or d

AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial
benzinga.com
AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial

AstraZeneca's EMERALD-3 trial shows improved progression-free survival with STRIDE, lenvatinib a